Adipokine profiles in preeclampsia

References

• ACOG. ACOG Practice Bulletin No. 125: chronic hypertension in pregnancy. Obstet Gynecol. 2012;119(2 Pt 1):396–407.
   PubMedGoogle Scholar
• ACOG. Task Force on Hypertension in Pregnancy. Report of the American College of Obstetricians and Gynecologists’ Task Force on Hypertension in Pregnancy. Obstet Gynecol. 2013;122(5):1122–1131.
   PubMed Web of Science ®Google Scholar
• D’Alton ME, Main EK, Menard MK, et al. The national partnership for maternal safety. Obstet Gynecol. 2014;123(5):973–977.
   PubMed Web of Science ®Google Scholar
• Fingar KR, Mabry-Hernandez I, Ngo-Metzger Q, et al. Delivery hospitalizations involving preeclampsia and eclampsia; 2005–2014: Statistical Brief # 222. Healthcare Cost and Utilization Project (HCUP) statistical briefs. Rockville (MD); 2006.
   Google Scholar
• Dietz WH. The response of the US Centers for Disease Control and Prevention to the obesity epidemic. Annu Rev Public Health. 2015;36(1):575–596.
   PubMed Web of Science ®Google Scholar
• Overcash RT, Lacoursiere DY. The clinical approach to obesity in pregnancy. Clin Obstet Gynecol. 2014;57(3):485–500.
   PubMed Web of Science ®Google Scholar
• Roberts JM, Bodnar LM, Patrick TE, et al. The role of obesity in preeclampsia. Pregnancy Hypertens. 2011;1(1):6–16.
   PubMed Web of Science ®Google Scholar
• Huda SS, Brodie LE, Sattar N. Obesity in pregnancy: prevalence and metabolic consequences. Semin Fetal Neonat Med. 2010;15(2):70–76.
   PubMed Web of Science ®Google Scholar
• Rasmussen KM, Abrams B, Bodnar LM, et al. Recommendations for weight gain during pregnancy in the context of the obesity epidemic. Obstet Gynecol. 2010;116(5):1191–1195.
   PubMed Web of Science ®Google Scholar
• Rasmussen KM, Catalano PM, Yaktine AL. New guidelines for weight gain during pregnancy: what obstetrician/gynecologists should know. Curr Opin Obstet Gynecol. 2009;21(6):521–526.
   PubMed Web of Science ®Google Scholar
• Weiss JL, Malone FD, Emig D, et al. Obesity, obstetric complications and cesarean delivery rate – a population-based screening study. Am J Obstet Gynecol. 2004;190(4):1091–1097.
   PubMed Web of Science ®Google Scholar
• Diaz AA, Young TP, Kurugol S, et al. Abdominal visceral adipose tissue is associated with myocardial infarction in patients with COPD. Chronic Obstr Pulm Dis. 2015;2(1):8–16.
   PubMed Web of Science ®Google Scholar
• Huda SS, Jordan F, Bray J, et al. Visceral adipose tissue activated macrophage content and inflammatory adipokine secretion is higher in pre-eclampsia than in healthy pregnancys. Clin Sci. 2017;131(13):1529–1540.
   PubMed Web of Science ®Google Scholar
• Fasshauer M, Waldeyer T, Seeger J, et al. Serum levels of the adipokine visfatin are increased in pre-eclampsia. Clin Endocrinol. 2008;69(1):69–73.
   PubMed Web of Science ®Google Scholar
• Ferreira AFA, Rezende JC, de Cassia C. Oliveira R, et al. Maternal serum visfatin at 11–13 weeks’ gestation in preeclampsia. J Hum Hypertens. 2013;27(4):261–264.
   PubMed Web of Science ®Google Scholar
• Fukuhara A, Matsuda M, Nishizawa M. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science. 2005;307(5708):426–430.
   PubMed Web of Science ®Google Scholar
• Borst SE, Conover CF, Bagby GJ. Association of resistin with visceral fat and muscle insulin resistance. Cytokine. 2005;32(1):39–44.
   PubMed Web of Science ®Google Scholar
• Marchi J, Berg M, Dencker A, et al. Risks associated with obesity in pregnancy, for the mother and baby: a systematic review of reviews. Obes Rev. 2015;16(8):621–638.
   PubMed Web of Science ®Google Scholar
• Gammill HS, Aydelotte TM, Guthrie KA, et al. Cellular fetal microchimerism in preeclampsia. Hypertension. 2013;62(6):1062–1067.
   PubMed Web of Science ®Google Scholar
• Seol HJ, Oh MJ, Yeo MK, et al. Comparison of serum levels and the placental expression of resistin between patients with preeclampsia and normal pregnant women. Hypertens Pregnancy. 2010;29(3):310–317.
   PubMed Web of Science ®Google Scholar
• Zulfıkaroglu E, Isman F, Payaslı A, et al. Plasma visfatin levels in preeclamptic and normal pregnancies. Arch Gynecol Obstet. 2010;281(6):995–998.
   PubMed Web of Science ®Google Scholar
• Seely EW, Solomon CG. Insulin resistance and its potential role in pregnancy-induced hypertension. J Clin Endocrinol Metab. 2003;88(6):2393–2398.
   PubMed Web of Science ®Google Scholar
• Solomon CG, Seely EW. Brief review: hypertension in pregnancy? Hypertension. 2001;37(2):232–239.
   PubMed Web of Science ®Google Scholar
• Song Y, Gao J, Qu Y, et al. Serum levels of leptin, adiponectin and resistin in relation to clinical characteristics in normal pregnancy and preeclampsia. Clin Chim Acta. 2016;458:133–137.
   PubMed Web of Science ®Google Scholar
• Zorba E, Vavilis D, Venetis CA, et al. Visfatin serum levels are increased in women with preeclampsia: a case-control study. J Matern Fetal Neonatal Med. 2012;25(9):1668–1673.
   PubMed Web of Science ®Google Scholar
• Christiansen M, Hedley PL, Placing S, et al. Maternal serum resistin is reduced in first trimester preeclampsia pregnancies and is a marker of clinical severity. Hypertens Pregnancy. 2015;34(4):422–433.
   PubMed Web of Science ®Google Scholar
• Chang YH, Chang DM, Lin KC, et al. Visfatin in overweight/obesity, type 2 diabetes mellitus, insulin resistance, metabolic syndrome and cardiovascular diseases: a meta-analysis and systemic review. Diabetes Metab Res Rev. 2011;27(6):515–527.
   PubMed Web of Science ®Google Scholar
• Jamar G, Caranti DA, de Cassia Cesar H, et al. Leptin as a cardiovascular risk marker in metabolically healthy obese. Appetite. 2017;108:477–482.
   PubMed Web of Science ®Google Scholar
• Vendrell J, Broch M, Vilarrasa N, et al. Resistin, adiponectin, ghrelin, leptin, and proinflammatory cytokines: relationships in obesity. Obes Res. 2004;12(6):962–971.
   PubMedGoogle Scholar
• Pavlová T, Novák J, Bienertová-Vašků J. The role of visfatin (PBEF/Nampt) in pregnancy complications. J Reprod Immunol. 2015;112:102–110.
   PubMed Web of Science ®Google Scholar